₹2,288.80
−1.76%NSE close, 16 Nov 2026
+59.12%
CORONA Remedies is a small cap company, listed on NSE under the symbol CORONA. At ₹2,288.80 a share, the market values the whole company at ₹13,998 crore.
In FY26, it reported sales of ₹1,403 crore and a net profit of ₹185 crore, an operating margin of 20.9%.
The market values the company at 67.6 times its profit over the last twelve months and 17.39 times its book value; its return on equity is 25.7% and its borrowings are 0.12 times its equity.
Promoters hold 69.00% of the shares. Foreign institutions hold 4.21%, and domestic institutions, mutual funds among them, 16.45%.
₹ crore. Consolidated figures.
Schedule of meet
Schedule of meet
Transcript
Link of Recording
| 78.5 |
| 83.2 |
| 62.0 |
| 93.1 |
| 96.0 |
| Operating margin | 21.7% | 24.3% | 17.6% | 22.0% | 21.7% |
|---|
| Other income | 2.3 | 2.2 | 4.1 | 3.2 | 2.5 |
|---|
| Interest | 1.9 | 1.7 | 1.4 | 2.7 | 2.8 |
|---|
| Depreciation | 9.2 | 9.5 | 10.3 | 13.2 | 15.1 |
|---|
| Profit before tax | 69.6 | 55.2 | 54.7 | 80.4 | 80.6 |
|---|
| Tax | 17.5 | 13.9 | 9.4 | 20.3 | 20.4 |
|---|
| Net profit | 52.3 | 41.3 | 45.3 | 60.1 | 60.3 |
|---|
| EPS (₹) | 8.55 | 6.75 | 7.41 | 9.83 | 9.86 |
|---|
₹ crore, financial years to March.
| Line | FY26 |
|---|---|
| Sales | 1,403 |
| Expenses | 1,110 |
| Operating profit | 293 |
| Operating margin | 20.9% |
| Other income | 10.7 |
| Interest | 7.0 |
| Depreciation | 37.9 |
| Profit before tax | 240 |
| Tax | 55.3 |
| Net profit | 185 |
| EPS (₹) | 30.27 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY26 | 6M to Sep 2026 |
|---|---|---|
| From operations | 229 | 113 |
| From investing | −256 | 3.3 |
| From financing | 25.3 | −116 |
| Spent on fixed assets | −174 | −26.3 |
| Free cash flow | 55.3 | 86.4 |
Margins, returns, debt, tax and cash.
| Line | FY26 |
|---|---|
| Net margin | 13.2% |
| Operating margin | 20.9% |
| Return on equity | 24.8% |
| Return on capital employed | 27.8% |
| Return on assets | 15.4% |
| Debt to equity | 0.19 |
| Interest coverage | 35.50 |
| Debt to assets | 0.12 |
| Current ratio | 0.96 |
| Quick ratio | 0.62 |
| Cash ratio | 0.01 |
| Asset turnover | 1.16 |
| Fixed asset turnover | 4.82 |
| Inventory turnover | 2.10 |
| Receivables turnover | 9.60 |
| Gross margin | 81.4% |
| Cash from operations to profit | 124.0% |
| Effective tax rate | 23.0% |
Unaudited Financial Results of the Company for second quarter and half year ended on September 30, 2026
The financial results for the period ended September 30, 2026.
Press Release on GMP Compliance Certification from Brazilian Health Regulatory Agency, ANVISA, Brazil
Receipt of GMP Compliance Certification from Brazilian Health Regulatory Agency, ANVISA, Brazil for OSD manufacturing facility and Hormone manufacturing facility of the Company, both located at Bhayla, Ahmedabad.
Significant increase in volume has been observed in CORONA Remedies Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to…
Significant increase in volume has been observed in CORONA Remedies Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to…
Machine Readable Financial results for Q1 2026-27